Drug profile · INN
linvoseltamab
LYNOZYFIC
linvoseltamab (LYNOZYFIC) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited.
Drug details — linvoseltamab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 16
- Data quality
- 0.89
Quick answer
linvoseltamab (LYNOZYFIC) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
EMA Conditional Marketing Authorization: Linvoseltamab for RRMM in EU
Linvoseltamab has received EMA's Conditional Marketing Authorization for treating relapsed/refractory multiple myeloma, offering new hope for patients in the EU.
PRAC Safety Signal Assessment: Insights on Bispecific Antibodies in Hematologic Malignancies
This article delves into PRAC's assessment of safety signals related to bispecific antibodies, focusing on their efficacy and safety in treating hematologic malignancies.
EMA Conditional Approval Pathway: Linvoseltamab and Oncology Access in EU
This article delves into the EMA's Conditional Approval Pathway, focusing on Linvoseltamab and its impact on oncology access across the European Union.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is linvoseltamab?
linvoseltamab (LYNOZYFIC) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited.
What is the brand name for linvoseltamab?
LYNOZYFIC is a marketed brand name for linvoseltamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.